Profound Medical Corp. (TSX:PRN)
Canada
· Delayed Price · Currency is CAD 8.68
-0.17 (-1.92%)
Mar 28, 2025, 3:59 PM EST
Profound Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 2.44 | 0.39 | 2 | 3.15 | 4.58 | Upgrade
|
| Other Revenue | 8.24 | 6.81 | 4.68 | 3.72 | 2.72 | Upgrade
|
| Revenue | 10.68 | 7.2 | 6.68 | 6.87 | 7.3 | Upgrade
|
| Revenue Growth (YoY) | 48.35% | 7.75% | -2.79% | -5.90% | 74.99% | Upgrade
|
| Cost of Revenue | 3.64 | 2.89 | 3.66 | 3.92 | 3.83 | Upgrade
|
| Gross Profit | 7.04 | 4.31 | 3.02 | 2.95 | 3.47 | Upgrade
|
| Selling, General & Admin | 23.13 | 18.54 | 17.93 | 17.97 | 12.43 | Upgrade
|
| Research & Development | 16.97 | 14.42 | 14.69 | 15.28 | 9.91 | Upgrade
|
| Operating Expenses | 40.1 | 32.96 | 32.62 | 33.24 | 22.34 | Upgrade
|
| Operating Income | -33.06 | -28.65 | -29.6 | -30.29 | -18.86 | Upgrade
|
| Interest Expense | - | - | -0.17 | -0.07 | -0.54 | Upgrade
|
| Interest & Investment Income | 1.44 | 0.78 | 0.8 | 0.21 | 0.69 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.81 | -0.58 | 3.1 | -0.29 | -2.54 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.02 | -0.16 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | -27.82 | -28.45 | -25.86 | -30.59 | -21.49 | Upgrade
|
| Impairment of Goodwill | - | - | -2.52 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.09 | Upgrade
|
| Pretax Income | -27.82 | -28.45 | -28.38 | -30.59 | -21.58 | Upgrade
|
| Income Tax Expense | -0 | -0.13 | 0.29 | 0.11 | 0.05 | Upgrade
|
| Net Income | -27.82 | -28.32 | -28.67 | -30.7 | -21.62 | Upgrade
|
| Net Income to Common | -27.82 | -28.32 | -28.67 | -30.7 | -21.62 | Upgrade
|
| Shares Outstanding (Basic) | 25 | 21 | 21 | 20 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 21 | 21 | 20 | 17 | Upgrade
|
| Shares Change (YoY) | 16.91% | 1.69% | 1.79% | 18.33% | 55.83% | Upgrade
|
| EPS (Basic) | -1.12 | -1.34 | -1.38 | -1.50 | -1.25 | Upgrade
|
| EPS (Diluted) | -1.12 | -1.34 | -1.38 | -1.50 | -1.25 | Upgrade
|
| Free Cash Flow | -23.45 | -22.61 | -25.8 | -22.39 | -20.57 | Upgrade
|
| Free Cash Flow Per Share | -0.95 | -1.07 | -1.24 | -1.09 | -1.19 | Upgrade
|
| Gross Margin | 65.89% | 59.90% | 45.22% | 42.95% | 47.56% | Upgrade
|
| Operating Margin | -309.57% | -397.99% | -443.08% | -440.73% | -258.26% | Upgrade
|
| Profit Margin | -260.45% | -393.43% | -429.11% | -446.66% | -296.03% | Upgrade
|
| Free Cash Flow Margin | -219.60% | -314.06% | -386.17% | -325.80% | -281.68% | Upgrade
|
| EBITDA | -32.13 | -27.72 | -28.83 | -29.61 | -18.36 | Upgrade
|
| EBITDA Margin | - | - | - | - | -251.34% | Upgrade
|
| D&A For EBITDA | 0.94 | 0.93 | 0.78 | 0.68 | 0.51 | Upgrade
|
| EBIT | -33.06 | -28.65 | -29.6 | -30.29 | -18.86 | Upgrade
|
| EBIT Margin | - | - | - | - | -258.26% | Upgrade
|
| Revenue as Reported | 10.68 | 7.2 | 6.68 | 6.87 | 7.3 | Upgrade
|
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.